Search Prime Grants

U01DA051126

Cooperative Agreement

Overview

Grant Description
National Drug Early Warning System (NDEWS) Covid-19 supplement.
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Place of Performance
Florida United States
Geographic Scope
State-Wide
Analysis Notes
Amendment Since initial award the End Date has been extended from 02/28/25 to 02/28/30 and the total obligations have increased 658% from $702,041 to $5,323,137.
University Of Florida was awarded National Drug Early Warning System Coordinating Center Cooperative Agreement U01DA051126 worth $5,323,137 from National Institute on Drug Abuse in April 2020 with work to be completed primarily in Florida United States. The grant has a duration of 9 years 10 months and was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs. The Cooperative Agreement was awarded through grant opportunity National Drug Early Warning System Coordinating Center (U01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 7/3/25

Period of Performance
4/1/20
Start Date
2/28/30
End Date
54.0% Complete

Funding Split
$5.3M
Federal Obligation
$0.0
Non-Federal Obligation
$5.3M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U01DA051126

Subgrant Awards

Disclosed subgrants for U01DA051126

Transaction History

Modifications to U01DA051126

Additional Detail

Award ID FAIN
U01DA051126
SAI Number
U01DA051126-150977078
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75N600 NIH National Insitute on Drug Abuse
Funding Office
75N600 NIH National Insitute on Drug Abuse
Awardee UEI
NNFQH1JAPEP3
Awardee CAGE
5E687
Performance District
FL-90
Senators
Marco Rubio
Rick Scott

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) Health research and training Grants, subsidies, and contributions (41.0) $2,691,414 100%
Modified: 7/3/25